Skip to content

Clinical trials

Fibromyalgia trials in the United States with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Fibromyalgia Phase: Not applicable Country / region: United States Clear all

164 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20022
20034
20043
20052
20067
20077
20081
200915
20105
20111
20122
20139
20148
20154
20164
20177
20187
201910
20207
20219
20227
20237
202412
202510
202612

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed102
Recruiting21
Unknown status11
Not yet recruiting9
Active, not recruiting7
Terminated7
Suspended4
Withdrawn2
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
University of Michigan11
Mayo Clinic9
VA Office of Research and Development9
Stanford University8
Icahn School of Medicine at Mount Sinai5
Brigham and Women's Hospital4
Cerephex Corporation4
Massachusetts General Hospital4
Spaulding Rehabilitation Hospital4
University of Kansas Medical Center4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Fibromyalgia164
Pain45
Chronic Pain37
Arthritis11
Fatigue11
Osteoarthritis11
Musculoskeletal Pain9
Arthritis, Rheumatoid8
Sleep Initiation and Maintenance Disorders8
Complex Regional Pain Syndromes6

Trials

Showing 1 to 25 of 164. Each trial links to its page on Pharma Observatory.

64 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.